| 27/03/24 | 14:18:54 | 27 Mar 2024 | | Result of AGM |
| 14/03/24 | 07:00:09 | 14 Mar 2024 | | Results of Fundraising |
| 13/03/24 | 16:45:26 | 13 Mar 2024 | | PrimaryBid Offer |
| 13/03/24 | 16:40:00 | 13 Mar 2024 | | Proposed Fundraising |
| 22/02/24 | 14:30:00 | 22 Feb 2024 | | Annual Report & Accounts |
| 17/01/24 | 07:00:06 | 17 Jan 2024 | | Preliminary Results and Notice of AGM |
| 21/12/23 | 07:20:56 | 21 Dec 2023 | | Notice of Results |
| 13/11/23 | 10:22:38 | 13 Nov 2023 | | Director/PDMR Shareholding |
| 08/11/23 | 07:00:15 | 8 Nov 2023 | | OBD strengths commercial leadership |
| 07/11/23 | 12:30:28 | 7 Nov 2023 | | Holding(s) in Company |
| 06/11/23 | 17:04:34 | 6 Nov 2023 | | Holding(s) in Company |
| 03/11/23 | 09:29:06 | 3 Nov 2023 | | Director/PDMR Shareholding |
| 23/10/23 | 11:09:28 | 23 Oct 2023 | | PDMR Dealing / Grant of Share Options |
| 20/10/23 | 09:45:45 | 20 Oct 2023 | | Director/PDMR Shareholding |
| 18/10/23 | 07:00:09 | 18 Oct 2023 | | Bupa UK to cover EpiSwitch® CiRT for customers |
| 06/10/23 | 17:44:36 | 6 Oct 2023 | | Director/PDMR Shareholding |
| 03/10/23 | 16:37:43 | 3 Oct 2023 | | Holding(s) in Company |
| 03/10/23 | 07:00:04 | 3 Oct 2023 | | OBD receives reimbursement code for PSE test |
| 26/09/23 | 07:00:07 | 26 Sept 2023 | | OBD launches 94% accurate PSE test in US and UK |
| 07/09/23 | 10:18:36 | 7 Sept 2023 | | Holding(s) in Company |
| 01/09/23 | 12:34:45 | 1 Sept 2023 | | Amendment: Director/PDMR Shareholding |
| 31/08/23 | 16:02:54 | 31 Aug 2023 | | Holding(s) in Company |
| 25/08/23 | 09:00:01 | 25 Aug 2023 | | Holding(s) in Company |
| 22/08/23 | 15:58:18 | 22 Aug 2023 | | Holding(s) in Company |
| 22/08/23 | 07:00:06 | 22 Aug 2023 | | Holding(s) in Company |
| 22/08/23 | 07:00:06 | 22 Aug 2023 | | Holding(s) in Company |
| 18/08/23 | 11:44:50 | 18 Aug 2023 | | Result of General Meeting |
| 08/08/23 | 16:00:31 | 8 Aug 2023 | | Holding(s) in Company |
| 04/08/23 | 07:00:06 | 4 Aug 2023 | | Results of PrimaryBid Offer |
| 02/08/23 | 07:00:06 | 2 Aug 2023 | | Result of Placing and Subscription |
| 01/08/23 | 16:55:57 | 1 Aug 2023 | | PrimaryBid Offer |
| 01/08/23 | 16:54:35 | 1 Aug 2023 | | Proposed Fundraising |
| 30/05/23 | 07:00:07 | 30 May 2023 | | Half-year Report |
| 16/05/23 | 07:00:10 | 16 May 2023 | | Notice of Interim Results and Investor Webinar |
| 15/05/23 | 07:00:05 | 15 May 2023 | | CiRT expanded validation for ICI immunotherapies |
| 02/05/23 | 07:00:12 | 2 May 2023 | | US PACT Award for prognosis test for IOrelated HPD |
| 18/04/23 | 07:00:06 | 18 Apr 2023 | | Director/PDMR Shareholding |
| 05/04/23 | 07:00:04 | 5 Apr 2023 | | Business update for PSE and CiRT tests |
| 30/03/23 | 13:04:01 | 30 Mar 2023 | | Result of AGM |
| 23/03/23 | 15:19:02 | 23 Mar 2023 | | Holding(s) in Company |
| 22/03/23 | 14:22:15 | 22 Mar 2023 | | Holding(s) in Company |
| 15/03/23 | 11:43:14 | 15 Mar 2023 | | AIM Rule 17 Schedule 2(g) Update |
| 03/03/23 | 16:33:11 | 3 Mar 2023 | | Publication of FY22 Annual Report |
| 23/02/23 | 10:36:48 | 23 Feb 2023 | | PDMR Dealing |
| 06/02/23 | 07:00:04 | 6 Feb 2023 | | OBD Prostate Screening EpiSwitch Blood Test Update |
| 27/01/23 | 14:36:02 | 27 Jan 2023 | | Director/PDMR Shareholding |
| 24/01/23 | 07:00:05 | 24 Jan 2023 | | Preliminary Results and Notice of AGM |
| 21/12/22 | 07:00:05 | 21 Dec 2022 | | Notice of FY22 Results and Investor Webinar |
| 19/12/22 | 07:00:08 | 19 Dec 2022 | | OBD in San Francisco for JPM Healthcare conf 2023 |
| 16/12/22 | 07:00:04 | 16 Dec 2022 | | Initial assessment of EpiSwitch assay in ALS trial |
